https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=13545
Document made available to the pharmacist to communicate a drug interaction to the doctor.
DOWNLOADRifampicin may induce P-gp and decrease the plasma concentration of Ledipasvir / Sofosbuvir.
Possible decrease of clinical efficacy.
–
–
–
Contraindicated. Use alternative.
–
–
–
Reference number |
---|
# patients |
HIV/HCV |
Dose |
Frequency |
Cmax |
AUC |
Duration (days) |
3073 | 3082 |
---|---|
31 | 17 |
- | - |
90 mg * | 400 mg ** |
x 1 * | x 1 ** |
- 35% * | - 77% ** † |
- 59% * | - 72% ** † |
3073 | 3082 |
---|---|
31 | 17 |
- | - |
600 mg | 600 mg |
QD | QD |
7 |
Ref #3073 : * Study conducted with ledipasvir administered as single agent and in the presence of two other investigational HCV direct-acting agents.
Ref #3082 : ** Study conducted with sofosbuvir administered as single agent.
† GS-331007, sofosbuvir active metabolite : AUC ±0% and Cmax +24%.